Respiratory Syncytial Virus Mrna Vaccine Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 0.5 mL

Reference Brands: mRESVIA (USA/EU)

Category: Vaccines

mRESVIA is an mRNA vaccine designed to protect adults against lower respiratory tract disease (LRTD) caused by RSV. It works by instructing the body to produce a harmless RSV F protein fragment, triggering immune protection. Administered as a single 0.5 mL intramuscular injection, it is indicated for adults 60 years and older and adults 18–59 at increased risk. It is the first non‑COVID‑19 mRNA vaccine approved in several regions. Common side effects include pain at injection site, fatigue, headache, and muscle aches. Respiratory syncytial virus mRNA vaccine is available in injection (prefilled syringe) and strengths such as 0.5 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Respiratory syncytial virus mRNA vaccine is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Respiratory syncytial virus mRNA vaccine can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

mRESVIA is a messenger RNA (mRNA) vaccine developed to actively immunize adults against lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV), which can cause severe lung infections, particularly in older adults and at-risk populations. The vaccine contains nucleoside-modified mRNA (mRNA‑1345) encoding a stabilized RSV F glycoprotein in its prefusion form. When administered as a 0.5 mL intramuscular injection, the mRNA instructs the recipient’s cells to produce the RSV F protein fragment, stimulating the immune system to generate protective antibodies without using live virus. mRESVIA is indicated for adults 60 years and older and adults 18 through 59 who are at increased risk of severe RSV disease. The vaccine may cause mild to moderate side effects such as pain at the injection site, fatigue, headache, muscle pain, joint pain, and chills. Its approval marks one of the first uses of mRNA technology for a disease other than COVID‑19, demonstrating the potential of mRNA vaccines to prevent other viral illnesses in adults.